Résumé
Purpose To investigate the clinical characteristics and Oxford classification of IgA nephropathy patients with hyperurice-mia. Methods 151 IgA nephropathy patients confirmed by renal biopsy in 2013 were analyzed retrospectively. The patients were di-vided into the two groups:IgA nephropathy patients with or without hyperuricemia. Morphological changes were evaluated with Oxford classification scoring system and Lee’s grades. A comparative analysis of clinical manifestations and pathological injuries was performed between the two groups. Results Incidence of hyperuricemia in IgA nephropathy patients was 48. 3% and was more common in young men. Hypertension was associated with hyperuricemia. Oxford classification of IgA nephropathy patients with hyperuricemia was pre-dominant M1E0S1T0 and Lee’s grades presented with grade Ⅲ. The outstanding histopathologic features with higher plasma uric acid levels indicated higher tubulointerstitial chronicity, higher glomerular sclerosis ratio, accompanied by a decline in glomerular filtration rate. There was no significant difference of vascular lesions. Conclusions The prevalence of hyperuricemia in IgA nephropathy pa-tients is high. Oxford classification shows IgA nephropathy with hyperuricemia are associated with more severe tubulointerstitial lesions and lower GFR.
Résumé
Objective To assess the efficacy of Xuezhikang capsule on hyperuricacidemia and its safety. Methods The study was designed as a random, double-blind placebo controlled clinical trial. 80 hyperuricacidemia patients were divided randomly into test group and control group (40 in test group and 40 in control group). The course of treatment was 28 days. Results 75 patients finished the trial (38 in test group and 37 in control group). After 28 days of treatment, the differences in reduction of UA, XOD, FINs, Homa-IR, TC, TG, Lp, CRP, ET, ?2-MG and elevation of HDL of the test group were statistic significance. No side effect was found in the trial. Conclusion Xuezhikang capsule has good clinical effect and safety in the treatment of hyperuricacidemia.